Humana Inc vs Royal Bank of Canada — how do they compare? Humana Inc trades at $445.06 (market cap $46.49B), while Royal Bank of Canada trades at $192.67 (market cap $262.99B). The key difference: Royal Bank of Canada is far larger — about 5.7× Humana Inc's market cap, and Royal Bank of Canada pays the higher dividend (2.66%). Which is the better fit depends on your goals — on Pluang, investors hold Humana Inc for 53 Days and Royal Bank of Canada for 47 Days on average.
| HUM | RY | |
|---|---|---|
Market Cap | $46.49B | $262.99B |
Volume | 2,567,704 | 1,016,377 |
Sector | Health | Financials |
52-Week High | $409.85 | $217.87 |
52-Week Low | $163.67 | $143.64 |
Typical Hold Time | 53 Days | 47 Days |
Enterprise Value | $53.84B | $730.11B |
Dividend Yield | 0.91% | 2.66% |
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $396.51, down 1.92% on the day, with strong technical momentum showing bullish moving averages and key support at $391. The company demonstrates consistent revenue growth reaching $129.7B in 2025, though net margins have compressed to 0.88%. Recent quarterly earnings have exceeded expectations, with Q2 2026 EPS of $7.61 beating estimates of $7.27. Analyst sentiment remains positive with a $432.63 consensus price target representing 9% upside potential from current levels.
The investment case centers on Humana's dominant Medicare Advantage position and consistent revenue growth, though margin pressure and regulatory scrutiny present headwinds. With 43% of analysts maintaining buy ratings and institutional accumulation continuing, the stock offers exposure to healthcare demographics but requires monitoring of enrollment trends and cost management execution.
Royal Bank of Canada (RY) trades at $191.22, down 2.61% on the day, amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, including Q2 2026 EPS of $3.07 versus $2.89 expected, and robust profitability with a 32.01% net income margin. Revenue growth accelerated to $66.53B in 2025, and the company maintains a solid dividend, with recent payouts of $1.76 per share. Analyst sentiment is mixed, with a Buy consensus of 43% but technical indicators pointing to near-term pressure.
RY presents a value opportunity with a reasonable P/E of 17.2 and strong ROE of 17.2%, supported by earnings momentum and strategic initiatives like global transaction banking integration. Risks include stretched valuations relative to peers, a high EV/EBITDA of 23.52, and macroeconomic sensitivity. The stock's current price near support at $189 suggests potential stability, but investors should weigh fundamental strength against technical bearishness and sector headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →